For LDL-C reduction in adult patients with hypercholesterolemia along with diet and exercise.1
Actor portrayals.
LOWER. LONGER. LEQVIO®.
Greater LDL-C reduction was maintained during each 6-month dosing interval vs placebo.1
LEQVIO is the only twice-yearly PCSK9 inhibitor therapy, after 2 initial doses.1
Are your patients ready to start LEQVIO? Find coverage in your area and fill out the Patient Start Form to begin.
“When I saw the LEQVIO commercial…2 doses a year,† I thought, 'Man, that's what I need to be on.'"
– Linda S., LEQVIO patient compensated for her time.
Individual results may vary.
†After 2 initial doses.
HCP, health care professional; LDL-C, low-density lipoprotein cholesterol; mAb, monoclonal antibody; PCSK9, proprotein convertase subtilisin/kexin type 9.